Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.
Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Atherosclerosis. 2024 Apr;391:117503. doi: 10.1016/j.atherosclerosis.2024.117503. Epub 2024 Feb 28.
Acetylcholine (ACh) provocation testing can detect vasomotor disorders in patients with ischemia and non-obstructed coronary arteries (INOCA) or myocardial infarction and non-obstructed coronary arteries (MINOCA). We aimed to derive and validate a simple risk score to predict a positive ACh test response.
We prospectively enrolled consecutive INOCA and MINOCA patients undergoing ACh provocation testing. Patients were split in two cohorts (derivation and validation) according to time of enrolment. The score was derived in 386 patients (derivation cohort) and then validated in 165 patients (validation cohort).
551 patients were enrolled, 371 (67.3%) INOCA and 180 (32.7%) MINOCA. ACh test was positive in 288 (52.3%) patients. MINOCA, myocardial bridge (MB), C-reactive protein (CRP) and dyslipidaemia were independent predictors of a positive ACh test in the derivation cohort. The ABCD (Acute presentation, Bridge, CRP, Dyslipidaemia) score was derived: 2 points were assigned to MINOCA, 3 to MB, 1 to elevated CRP and 1 to dyslipidaemia. The ABCD score accurately identified patients with a positive ACh test response with an AUC of 0.703 (CI 95% 0.652-0.754,p < 0.001) in the derivation cohort, and 0.705 (CI 95% 0.626-0.784, p < 0.001) in the validation cohort. In the whole population, an ABCD score ≥4 portended 94.3% risk of a positive ACh test and all patients with an ABCD score ≥6 presented a positive test.
The ABCD score could avoid the need of ACh provocation testing in patients with a high score, reducing procedural risks, time, and costs, and allowing the implementation of a tailored treatment strategy. These results are hypothesis generating and further research involving larger cohorts and multicentre trials is needed to validate and refine the ABCD score.
乙酰胆碱(ACh)激发试验可检测到缺血且无阻塞性冠状动脉(INOCA)或心肌梗死且无阻塞性冠状动脉(MINOCA)患者的血管运动障碍。我们旨在制定并验证一个简单的风险评分,以预测 ACh 试验阳性反应。
我们前瞻性纳入了接受 ACh 激发试验的连续 INOCA 和 MINOCA 患者。根据入组时间,患者分为两个队列(推导和验证)。评分在 386 例患者(推导队列)中推导,然后在 165 例患者(验证队列)中验证。
共纳入 551 例患者,371 例(67.3%)为 INOCA,180 例(32.7%)为 MINOCA。288 例(52.3%)患者的 ACh 试验为阳性。MINOCA、心肌桥(MB)、C 反应蛋白(CRP)和血脂异常是推导队列中 ACh 试验阳性的独立预测因素。推导了 ABCD(急性发作、桥、CRP、血脂异常)评分:MINOCA 记 2 分,MB 记 3 分,CRP 升高记 1 分,血脂异常记 1 分。ABCD 评分准确识别出 ACh 试验阳性反应的患者,在推导队列中的 AUC 为 0.703(95%CI 0.652-0.754,p<0.001),在验证队列中的 AUC 为 0.705(95%CI 0.626-0.784,p<0.001)。在整个人群中,ABCD 评分≥4 预示着 ACh 试验阳性的风险为 94.3%,所有 ABCD 评分≥6 的患者均进行了阳性试验。
ABCD 评分可避免对评分较高的患者进行 ACh 激发试验,降低操作风险、时间和成本,并允许实施针对性的治疗策略。这些结果只是初步的,需要进一步涉及更大队列和多中心试验的研究来验证和完善 ABCD 评分。